DOP2011000052A - Metodo de identificacion de factores de riesgo de la enfermedad - Google Patents
Metodo de identificacion de factores de riesgo de la enfermedadInfo
- Publication number
- DOP2011000052A DOP2011000052A DO2011000052A DO2011000052A DOP2011000052A DO P2011000052 A DOP2011000052 A DO P2011000052A DO 2011000052 A DO2011000052 A DO 2011000052A DO 2011000052 A DO2011000052 A DO 2011000052A DO P2011000052 A DOP2011000052 A DO P2011000052A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- disease
- identification
- genetic variant
- alzheimer
- interest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
Aquí se proporciona un método para la identificación de una variante genética que está asociada con el desarrollo de un padecimiento de interés (por ejemplo, la enfermedad de Alzheimer), y las variantes genéticas identificadas de esta manera. También se proporcionan métodos de tratamiento con un ingrediente activo (por ejemplo, con un agente activo particular y/o en una etapa más temprana), al momento de detectar una variante genética aquí descrita. En algunas modalidades, la variante genética es un polimorfismo de eliminación/inserción (DIP) del gen TOMM4O. También se proporcionan los equipos para determinar si un sujeto se encuentra en un riesgo aumentado de desarrollar la enfermedad de Alzheimer de presentación tardía. Además se proporcionan equipos para determinar si un sujeto actúa en respuesta al tratamiento para un padecimiento de interés con un agente activo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8820308P | 2008-08-12 | 2008-08-12 | |
US18667309P | 2009-06-12 | 2009-06-12 | |
US22464709P | 2009-07-10 | 2009-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000052A true DOP2011000052A (es) | 2011-04-15 |
Family
ID=41669605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000052A DOP2011000052A (es) | 2008-08-12 | 2011-02-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
Country Status (32)
Country | Link |
---|---|
US (4) | US8815508B2 (es) |
EP (2) | EP2789695B1 (es) |
JP (4) | JP5833922B2 (es) |
KR (3) | KR101729340B1 (es) |
CN (3) | CN102177436B (es) |
AU (3) | AU2009282114B2 (es) |
BR (1) | BRPI0917948A2 (es) |
CA (1) | CA2735578C (es) |
CL (1) | CL2011000298A1 (es) |
CO (1) | CO6351823A2 (es) |
CY (1) | CY1115412T1 (es) |
DK (1) | DK2324126T3 (es) |
DO (1) | DOP2011000052A (es) |
EA (1) | EA021399B1 (es) |
ES (1) | ES2463766T3 (es) |
GE (1) | GEP20146107B (es) |
HK (1) | HK1153511A1 (es) |
HR (1) | HRP20140709T1 (es) |
IL (2) | IL211140A (es) |
MA (1) | MA32619B1 (es) |
ME (1) | ME01898B (es) |
MX (1) | MX2011001671A (es) |
NZ (3) | NZ710443A (es) |
PE (3) | PE20110565A1 (es) |
PL (1) | PL2324126T3 (es) |
PT (1) | PT2324126E (es) |
RS (1) | RS53383B (es) |
SG (1) | SG193793A1 (es) |
SI (1) | SI2324126T1 (es) |
SM (1) | SMT201400088B (es) |
WO (1) | WO2010019550A2 (es) |
ZA (1) | ZA201101095B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102177436B (zh) | 2008-08-12 | 2015-05-13 | 金帆德尔制药股份有限公司 | 鉴定疾病风险因子的方法 |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
KR102218512B1 (ko) | 2010-05-25 | 2021-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
AU2013204020B2 (en) * | 2011-01-10 | 2016-03-31 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
SG191399A1 (en) | 2011-01-10 | 2013-08-30 | Zinfandel Pharmaceuticals Inc | Methods and drug products for treating alzheimer's disease |
AU2011354696B2 (en) * | 2011-01-10 | 2015-03-05 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
US20120231457A1 (en) * | 2011-03-10 | 2012-09-13 | Nikolaos Tezapsidis | Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load) |
US8718950B2 (en) | 2011-07-08 | 2014-05-06 | The Medical College Of Wisconsin, Inc. | Methods and apparatus for identification of disease associated mutations |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
JP2015505314A (ja) * | 2012-01-09 | 2015-02-19 | 武田薬品工業株式会社 | アルツハイマー病を治療する方法及び医薬品 |
GB201209689D0 (en) * | 2012-05-31 | 2012-07-18 | Imp Innovations Ltd | Methods |
EP2962270A4 (en) | 2013-03-01 | 2016-08-24 | Actx Inc | CLOUD-ARTIGER MEDICAL INFORMATION SERVICE |
JPWO2015174544A1 (ja) * | 2014-05-16 | 2017-04-20 | 国立研究開発法人国立精神・神経医療研究センター | 精神疾患判定マーカー |
US11214829B2 (en) | 2015-07-23 | 2022-01-04 | Asuragen, Inc. | Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating A/T-rich segments |
US11549146B2 (en) | 2016-05-20 | 2023-01-10 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
CN105969885A (zh) * | 2016-06-24 | 2016-09-28 | 江苏雄鸣医药科技有限公司 | 一种阿尔兹海默症的基因诊断试剂盒 |
WO2018132755A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease |
AU2018239433B2 (en) | 2017-03-21 | 2024-02-01 | Indiana University Research And Technology Corporation | A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof |
WO2019028080A1 (en) * | 2017-07-31 | 2019-02-07 | Quest Diagnostics Investments Llc | DETECTION OF THE ISOTYPE OF APOLIPOPROTEIN E BY MASS SPECTROMETRY |
CN111247595A (zh) * | 2017-10-31 | 2020-06-05 | 通用电气健康护理有限公司 | 用于诊断认知疾病病理和/或结果的医疗系统 |
AU2019215046A1 (en) * | 2018-01-31 | 2020-09-17 | Francisco Vazquez Barreiros | Early feedback of disease factors to improve patient quality of life, engagement and persistence |
KR102303638B1 (ko) * | 2018-04-13 | 2021-09-23 | 사회복지법인 삼성생명공익재단 | 알츠하이머성 치매가 발병될 가능성 평가방법 |
US20210230696A1 (en) | 2018-05-07 | 2021-07-29 | Biotx.Ai Gmbh | Method for predicting the risk of late-onset alzheimer's diseases |
WO2019222754A1 (en) * | 2018-05-18 | 2019-11-21 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
EP3626835A1 (en) * | 2018-09-18 | 2020-03-25 | Sistemas Genómicos, S.L. | Method for genotypically identifying both alleles of at least one locus of a subject's hla gene |
KR102127903B1 (ko) * | 2019-01-29 | 2020-06-29 | 연세대학교 산학협력단 | 염증성 호흡기 질환의 진단용 바이오마커 |
CA3141888A1 (en) * | 2019-05-30 | 2020-12-03 | The University Of Newcastle | A method of treatment or prophylaxis |
CN111187825A (zh) * | 2020-01-15 | 2020-05-22 | 丁玎 | 阿尔兹海默症的tomm40基因及apoe基因的易感位点的检测方法及试剂盒 |
CN111593107A (zh) * | 2020-01-15 | 2020-08-28 | 丁玎 | 阿尔兹海默症易感位点rs10119与rs71352238的检测方法及试剂盒 |
KR102535235B1 (ko) * | 2020-11-25 | 2023-05-26 | 서울대학교산학협력단 | 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도 |
RU2757522C1 (ru) * | 2021-06-02 | 2021-10-18 | Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) | СПОСОБ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1 и 2 ТИПА (варианты) |
KR20230150497A (ko) * | 2022-04-22 | 2023-10-31 | 사회복지법인 삼성생명공익재단 | 유럽-동아시아인 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US663780A (en) * | 1898-09-09 | 1900-12-11 | Wheeler & Wilson Mfg Co | Trimming attachment for sewing-machines. |
US4302204A (en) | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
FI63596C (fi) | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
US4994373A (en) | 1983-01-27 | 1991-02-19 | Enzo Biochem, Inc. | Method and structures employing chemically-labelled polynucleotide probes |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US6060237A (en) | 1985-02-26 | 2000-05-09 | Biostar, Inc. | Devices and methods for optical detection of nucleic acid hybridization |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5112460A (en) | 1986-10-21 | 1992-05-12 | Northeastern University | High performance microcapillary gel electrophoresis |
DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
US5595883A (en) | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
TW263504B (es) | 1991-10-03 | 1995-11-21 | Pfizer | |
US5326770A (en) | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
ZA936492B (en) | 1992-09-10 | 1995-03-02 | Lilly Co Eli | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. |
ATE262592T1 (de) | 1992-10-13 | 2004-04-15 | Univ Duke | Verfahren zum nachweis der alzheimer krankheit |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
US6128587A (en) | 1997-01-14 | 2000-10-03 | The Regents Of The University Of California | Method and apparatus using Bayesian subfamily identification for sequence analysis |
US5904824A (en) | 1997-03-07 | 1999-05-18 | Beckman Instruments, Inc. | Microfluidic electrophoresis device |
EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
EP0869122B1 (en) | 1997-03-31 | 2002-12-04 | Korea Research Institute Of Chemical Technology | Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof |
EP1047423B1 (en) * | 1997-11-19 | 2006-05-10 | Takeda Pharmaceutical Company Limited | Novel apoptosis inhibitors |
US7122373B1 (en) | 1998-05-14 | 2006-10-17 | Nuvelo, Inc. | Human genes and gene expression products V |
US6964868B1 (en) | 1998-01-28 | 2005-11-15 | Nuvelo, Inc. | Human genes and gene expression products II |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
CA2330829C (en) | 1998-06-16 | 2011-08-02 | Nova Molecular, Inc. | Methods for treating a neurological disease by determining bche genotype |
AU773765B2 (en) | 1998-10-01 | 2004-06-03 | Variagenics, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele |
AU771187B2 (en) | 1998-11-10 | 2004-03-18 | Genset | Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait |
US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
CN1078616C (zh) * | 1998-12-16 | 2002-01-30 | 中国科学院上海生命科学研究中心 | 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒 |
JP2000273040A (ja) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | トログリタゾンを含有するアポトーシス抑制剤 |
US6401043B1 (en) | 1999-04-26 | 2002-06-04 | Variagenics, Inc. | Variance scanning method for identifying gene sequence variances |
CA2371391A1 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
DE19936719A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6532467B1 (en) | 2000-04-10 | 2003-03-11 | Sas Institute Inc. | Method for selecting node variables in a binary decision tree structure |
US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
US20040122091A1 (en) | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
JP2004511453A (ja) | 2000-10-11 | 2004-04-15 | エスペリオン セラピューティクス,インコーポレイテッド | コレステロールの制御及び関連する使用のためのケトン化合物及び組成物 |
JP2004532799A (ja) | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス,インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
CN100577174C (zh) | 2000-11-24 | 2010-01-06 | 脉管生物生长有限公司 | 含有限定的氧化磷脂的组合物 |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6495335B2 (en) | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
US20040204502A1 (en) | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20050020694A1 (en) | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6828462B2 (en) | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
US7132244B2 (en) | 2001-11-21 | 2006-11-07 | Syn X Pharma, Inc. | Betaine/GABA transport protein biopolymer marker indicative of insulin resistance |
US7052849B2 (en) | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
US7135297B2 (en) | 2001-11-23 | 2006-11-14 | Nanogen Inc. | Protein biopolymer markers indicative of insulin resistance |
US20030220374A1 (en) | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
WO2004005510A1 (ja) | 2002-07-05 | 2004-01-15 | Shionogi & Co., Ltd. | 新規Nogo受容体様ポリペプチドおよびそのDNA |
US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
CN100571701C (zh) * | 2002-12-24 | 2009-12-23 | 贝卢斯健康(国际)有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
CA2515783A1 (en) | 2003-02-14 | 2004-09-02 | Intergenetics Incorporated | Statistically identifying an increased risk for disease |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US20050004179A1 (en) | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
WO2005003766A2 (en) | 2003-06-13 | 2005-01-13 | Whitehead Institute For Biomedical Research | Methods of regulating metabolism and mitochondrial function |
TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
AU2005208566A1 (en) | 2004-01-22 | 2005-08-11 | Genaissance Pharmaceuticals, Inc. | APOE genetic markers associated with age of onset of Alzheimer's Disease |
TW200538738A (en) | 2004-02-20 | 2005-12-01 | Univ California | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
WO2006054297A2 (en) | 2004-11-17 | 2006-05-26 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US20060228728A1 (en) | 2005-01-31 | 2006-10-12 | Perlegen Sciences, Inc. | Genetic basis of Alzheimer's disease and diagnosis and treatment thereof |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EA200800879A1 (ru) | 2005-09-22 | 2008-10-30 | ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
US7608412B2 (en) | 2005-10-05 | 2009-10-27 | Auburn University | P62 as a diagnostic tool for alzheimer's disease |
NZ571871A (en) | 2006-03-16 | 2011-07-29 | Metabolic Solutions Dev Co | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
US20080045582A1 (en) | 2006-05-15 | 2008-02-21 | Issam Zineh | ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools |
JP5123936B2 (ja) | 2006-05-30 | 2013-01-23 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 認知症の検出および治療 |
US7651840B2 (en) * | 2006-07-14 | 2010-01-26 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
WO2008036678A2 (en) | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
US20090042849A1 (en) | 2006-12-06 | 2009-02-12 | Yochai Birnbaum | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof |
US7794937B2 (en) | 2006-12-22 | 2010-09-14 | Quest Diagnostics Investments Incorporated | Cystic fibrosis transmembrane conductance regulator gene mutations |
GB0702537D0 (en) | 2007-02-12 | 2007-03-21 | Leuven K U Res & Dev | Treatment for excessive adiposity |
US20080286876A1 (en) | 2007-05-14 | 2008-11-20 | Chissoe Stephanie | GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip |
WO2008147562A2 (en) | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
TW200914006A (en) | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
CN102177436B (zh) * | 2008-08-12 | 2015-05-13 | 金帆德尔制药股份有限公司 | 鉴定疾病风险因子的方法 |
US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
US20100136584A1 (en) | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
BRPI0919882A8 (pt) | 2008-10-30 | 2017-09-19 | Caris Life Sciences Luxembourg Holdings | Métodos para avaliar padrões de rna |
EP3181705A1 (en) | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
US9035048B2 (en) | 2008-12-12 | 2015-05-19 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with AMPK activity |
WO2010100653A2 (en) | 2009-02-02 | 2010-09-10 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
EP2422199B1 (en) | 2009-04-23 | 2018-07-25 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
CA2709621A1 (en) | 2009-09-11 | 2011-03-11 | Electrophoretics Limited | Markers and methods relating to the assessment of alzheimer's disease |
US20110195401A1 (en) | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Systems and methods for determining food allergies |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
SG191399A1 (en) * | 2011-01-10 | 2013-08-30 | Zinfandel Pharmaceuticals Inc | Methods and drug products for treating alzheimer's disease |
-
2009
- 2009-08-11 CN CN200980140279.0A patent/CN102177436B/zh not_active Expired - Fee Related
- 2009-08-11 NZ NZ710443A patent/NZ710443A/en not_active IP Right Cessation
- 2009-08-11 ME MEP-2014-70A patent/ME01898B/me unknown
- 2009-08-11 MX MX2011001671A patent/MX2011001671A/es active IP Right Grant
- 2009-08-11 NZ NZ619895A patent/NZ619895A/en not_active IP Right Cessation
- 2009-08-11 CN CN201510173806.5A patent/CN104805198B/zh not_active Expired - Fee Related
- 2009-08-11 JP JP2011523086A patent/JP5833922B2/ja active Active
- 2009-08-11 EP EP14165474.9A patent/EP2789695B1/en active Active
- 2009-08-11 PL PL09807152T patent/PL2324126T3/pl unknown
- 2009-08-11 BR BRPI0917948A patent/BRPI0917948A2/pt not_active Application Discontinuation
- 2009-08-11 PE PE2011000157A patent/PE20110565A1/es not_active Application Discontinuation
- 2009-08-11 ES ES09807152.5T patent/ES2463766T3/es active Active
- 2009-08-11 KR KR1020117005712A patent/KR101729340B1/ko active IP Right Grant
- 2009-08-11 KR KR1020167030021A patent/KR20160127181A/ko active Search and Examination
- 2009-08-11 NZ NZ591107A patent/NZ591107A/xx not_active IP Right Cessation
- 2009-08-11 SG SG2013061254A patent/SG193793A1/en unknown
- 2009-08-11 GE GEAP200912125A patent/GEP20146107B/en unknown
- 2009-08-11 PT PT98071525T patent/PT2324126E/pt unknown
- 2009-08-11 DK DK09807152.5T patent/DK2324126T3/da active
- 2009-08-11 CN CN201510007052.6A patent/CN104611421B/zh not_active Expired - Fee Related
- 2009-08-11 AU AU2009282114A patent/AU2009282114B2/en not_active Ceased
- 2009-08-11 PE PE2015000030A patent/PE20150362A1/es not_active Application Discontinuation
- 2009-08-11 KR KR1020187013536A patent/KR20180053432A/ko not_active Application Discontinuation
- 2009-08-11 EP EP09807152.5A patent/EP2324126B1/en active Active
- 2009-08-11 RS RS20140335A patent/RS53383B/en unknown
- 2009-08-11 EA EA201170332A patent/EA021399B1/ru not_active IP Right Cessation
- 2009-08-11 WO PCT/US2009/053373 patent/WO2010019550A2/en active Application Filing
- 2009-08-11 US US13/058,724 patent/US8815508B2/en active Active
- 2009-08-11 CA CA2735578A patent/CA2735578C/en not_active Expired - Fee Related
- 2009-08-11 PE PE2015002280A patent/PE20151924A1/es unknown
- 2009-08-11 SI SI200930940T patent/SI2324126T1/sl unknown
-
2011
- 2011-02-09 IL IL211140A patent/IL211140A/en active IP Right Grant
- 2011-02-10 ZA ZA2011/01095A patent/ZA201101095B/en unknown
- 2011-02-11 CL CL2011000298A patent/CL2011000298A1/es unknown
- 2011-02-11 DO DO2011000052A patent/DOP2011000052A/es unknown
- 2011-03-07 MA MA33680A patent/MA32619B1/fr unknown
- 2011-03-09 CO CO11028662A patent/CO6351823A2/es not_active Application Discontinuation
- 2011-07-21 HK HK11107605.9A patent/HK1153511A1/xx not_active IP Right Cessation
-
2014
- 2014-07-09 SM SM201400088T patent/SMT201400088B/xx unknown
- 2014-07-16 US US14/332,867 patent/US20150073025A1/en not_active Abandoned
- 2014-07-22 HR HRP20140709AT patent/HRP20140709T1/hr unknown
- 2014-07-22 CY CY20141100549T patent/CY1115412T1/el unknown
-
2015
- 2015-06-08 IL IL239277A patent/IL239277A0/en unknown
- 2015-10-29 JP JP2015212976A patent/JP2016047058A/ja active Pending
-
2016
- 2016-07-06 AU AU2016204678A patent/AU2016204678B2/en not_active Ceased
-
2017
- 2017-11-10 JP JP2017217336A patent/JP2018075005A/ja active Pending
-
2018
- 2018-04-04 AU AU2018202373A patent/AU2018202373A1/en not_active Abandoned
- 2018-06-28 US US16/021,261 patent/US10865449B2/en active Active
- 2018-12-05 JP JP2018228465A patent/JP6815372B2/ja active Active
-
2020
- 2020-11-13 US US17/097,705 patent/US20210095345A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000052A (es) | Metodo de identificacion de factores de riesgo de la enfermedad | |
UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
CO6331372A2 (es) | Inhibidor de parp 4-yodo-3-nitrobenzamida o un metabolito de la misma | |
MA40819B1 (fr) | Variant d'arni | |
CY1117721T1 (el) | Κυτταρα προελευσης αμνιακου υγρου | |
CR9315A (es) | Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia | |
CO6640308A2 (es) | Método de entrega de sistemas de soporte de decision (dss) y expedientes electrónicos de salud (ehr) para cuidado reproductivo, cuidato preconceptivo, tratamientos de fertilidad y otras condiciones de salud | |
MA29528B1 (fr) | Agents de fixation | |
CY1112579T1 (el) | Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας | |
CO2021009163A2 (es) | Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas | |
BRPI0710123A2 (pt) | Previsão de heterose e outros traços por análise de transcriptoma. | |
ES2572372T3 (es) | Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1 | |
MX2009009207A (es) | Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. | |
ECSP056189A (es) | Composiciones y método para el tratamiento de infecciones en ganado vacuno y porcino | |
CU23815A3 (es) | Diarilureas para el tratamiento de hipertensión pulmonar | |
ECSP077836A (es) | Compuestos mejorados farmacocinéticamente | |
CL2008001057A1 (es) | Agente para el tratamiento de micosis producida por saprolegnia, achlya y/o aphanomyces en peces, el cual comprende al menos un fungicida seleccionado entre a) inhibidores de l a mitosis y division celular, b) inhiidores de la sintesis de ergosterol o, c) derivados de piridina, benzopiranona, carbonitrilo,quinolinas, entre otras. | |
CL2007003800A1 (es) | Metodo para el tratamiento de la hipertension ocular que comprende un agente de molecula pequena que interactua con un gen que codifica para la proteina amiloide serica a (saa). | |
BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
CL2013000709A1 (es) | Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10). | |
AR064269A1 (es) | Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion | |
ECSP11010884A (es) | Método de identificación de factores de riesgo de la enfermedad | |
NO20082129L (no) | Middel til nedbrytning av nukleinsyrer samt fremgangsmate for nedbrytning av nukleinsyrer | |
MX358594B (es) | Factores de riesgo de enfermedad y métodos de uso. | |
CR20130199A (es) | Mètodo de indentificaciòn de factores de riesgo de la enfermedad |